About Foundayo

The First Oral GLP-1 Weight Loss Pill Has Arrived: What You Need to Know About Foundayo

Published by SkinnyJab | May 2026

 

The weight loss treatment landscape has just changed in a significant way. On 1 April 2026, the US Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) — a once-daily oral GLP-1 receptor agonist developed by Eli Lilly, the same pharmaceutical company behind Mounjaro. For the millions of people who have been reluctant to pursue injectable weight loss treatment, or who are looking for a more convenient long-term option, this represents a genuinely meaningful development.

At SkinnyJab, we believe our patients deserve clear, evidence-based information about advances in their field. In this post, we explain what Foundayo is, what the clinical trial data shows, how it compares to existing treatments, and what it may mean for those currently on — or considering — a medically supervised weight loss programme.

 

What Is Foundayo?

Foundayo is the brand name for orforglipron, a small molecule GLP-1 (glucagon-like peptide-1) receptor agonist. Unlike Mounjaro (tirzepatide) and Wegovy (semaglutide), which are administered via weekly subcutaneous injection, Foundayo is taken as a simple oral tablet once a day.

What makes it particularly notable is its convenience profile. Foundayo can be taken at any time of day, without any requirement to fast beforehand or restrict fluid intake — a meaningful distinction from the existing oral semaglutide tablet, which requires patients to take it on an empty stomach and wait 30 minutes before eating or drinking. For patients managing busy lifestyles, this flexibility is clinically and practically significant.

 

How Does It Work?

Like all GLP-1 receptor agonists, Foundayo works by mimicking the GLP-1 hormone that the body naturally produces in response to eating. By activating GLP-1 receptors, it helps to reduce appetite, slow gastric emptying (meaning food stays in the stomach for longer, promoting a feeling of fullness), and modulate the hormonal signals that drive hunger. Unlike Mounjaro, which targets both GLP-1 and GIP receptors, Foundayo targets GLP-1 only — making it more directly comparable to semaglutide in its mechanism of action, but delivered in a radically more convenient format.

 

What Do the Clinical Trials Show?

Foundayo has been through an extensive Phase 3 clinical trial programme, and the results are robust. In the landmark ATTAIN-1 trial, conducted across more than 3,000 adults with obesity or overweight with a weight-related medical condition, participants taking the highest dose of orforglipron lost an average of 27.3 lbs (approximately 12.4 kg) — representing 12.4% of their body weight — over 72 weeks, compared to just 2.2 lbs in the placebo group. All three doses tested in the trial met both the primary endpoint and all key secondary endpoints, and the treatment demonstrated significant improvements in cardiometabolic risk markers including blood pressure, cholesterol, and blood glucose levels.

The side effect profile was consistent with what is seen across the GLP-1 class of medicines — principally gastrointestinal effects such as nausea, which were most common during the dose escalation phase and generally resolved over time.

 

Can It Be Used for Weight Maintenance?

This is a question we have already been receiving from patients, and the answer is an encouraging one. A separate Phase 3 study investigated whether orforglipron could be used to maintain weight loss in patients who had previously achieved a weight plateau on injectable GLP-1 therapy — specifically Wegovy or Mounjaro. The results showed that orforglipron met its primary endpoint of superior weight maintenance compared to placebo over 52 weeks, meaning patients who switched from injectable therapy to Foundayo were able to hold on to the weight they had already lost. This is a clinically significant finding, as it opens a credible pathway for patients to transition from weekly injections to a daily oral pill for long-term maintenance — a question that sits at the heart of managing obesity as the chronic, ongoing condition that it is.

 

How Does It Compare to Mounjaro?

It is worth being clear that Mounjaro (tirzepatide) and Foundayo (orforglipron) are different medicines with different mechanisms, and direct comparisons should be interpreted carefully. Mounjaro, as a dual GIP and GLP-1 receptor agonist, has produced some of the highest weight loss results seen in any clinical trial to date — with average losses of up to 22.5% of body weight at the highest dose. Foundayo's 12.4% average weight loss figure, while clinically meaningful, is lower than this. However, the comparison is not straightforward, as trial populations, dosing schedules, and duration differ between studies.

What Foundayo offers that Mounjaro does not is the oral route of administration — a factor that for many patients is not a minor lifestyle preference but a genuine barrier to starting or sustaining treatment. If the choice is between an injection someone will never take and a pill they will take every day, the pill is the more effective medicine in practice, regardless of what the trial numbers say in isolation.

 

Is Foundayo Available in the UK?

At present, Foundayo has received FDA approval in the United States. UK approval is granted by the Medicines and Healthcare products Regulatory Agency (MHRA), which operates an independent review process. Eli Lilly has indicated that regulatory submissions to global agencies — including the MHRA — are being pursued, and given the speed and strength of the clinical data, UK approval is anticipated to follow.

At SkinnyJab, we are monitoring this closely and will communicate with our patients as soon as UK availability is confirmed. We would caution against sourcing any unlicensed or unregulated version of this medicine in the interim — as with all GLP-1 treatments, the safety of our patients depends on access through properly regulated, clinically supervised channels.

 

Who Might Benefit From Foundayo?

Once available in the UK through appropriate prescribing channels, Foundayo may be particularly suitable for patients who have been reluctant to pursue injectable treatment due to needle phobia or practical inconvenience, patients currently on injectable GLP-1 therapy who are looking to transition to an oral maintenance option, patients who travel frequently or have lifestyles where weekly injections are logistically difficult, and patients for whom the absence of food or water restrictions with dosing is an important factor in adherence.

As with all treatments at SkinnyJab, eligibility will be assessed on an individual clinical basis. No treatment is appropriate for everyone, and our clinicians will always take a thorough history, assess your clinical parameters, and discuss the full range of options before making any prescribing decision.

 

What Should You Do Now?

If this development has prompted questions about your own treatment plan — whether you are currently a patient at SkinnyJab or are considering starting a medically supervised weight loss programme — we would encourage you to book a consultation. Our clinical team stays at the leading edge of developments in this field precisely so that we can offer our patients the most informed, up-to-date guidance available.

The arrival of an effective oral GLP-1 option is a significant moment for obesity medicine. It will not be the right choice for every patient, but for many, it may be the option that finally makes treatment feel accessible.

 

This blog post is intended for informational purposes only and does not constitute medical advice. Foundayo (orforglipron) is not yet licensed for use in the UK. Any treatment decisions should be made in consultation with a qualified clinician. SkinnyJab is a private weight loss clinic offering medically supervised treatment programmes.